We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 164.80 | 164.80 | 165.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
Vectura Group PLC (VEC.LN) said Friday that it is due to receive $2.5 million from drugmaker Novartis AG (NOVN.EB) after an asthma medication met a regulatory milestone.
The company, which specializes in inhaled medicines, licensed the proposed inhaled asthma therapy, QVM149, to Novartis in 2005, and is responsible for the development and commercialization of the product. The payment was triggered by the acceptance by European Union regulatory authorities of a marketing authorization application for the proposed drug.
Should QVM149 be approved in the EU it will receive another $5 million, plus royalties on sales.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
May 24, 2019 03:21 ET (07:21 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Vectura Chart |
1 Month Vectura Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
